Continuous Erector Spinae Plane Blocks to Treat Pain Following Percutaneous Nephrolithotomy

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, triple-masked, placebo-controlled parallel-arm human subjects clinical trial investigating the addition of a continuous erector spinae plane nerve block to a single-injection erector spinae plane block to provide postoperative analgesia following percutaneous nephrolithotomy. Participants will all receive a single-injection nerve block and perineural catheter insertion. Following surgery, participants will be randomly allocated to receive either perineural local anesthetic or normal saline until the second day following surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• undergoing unilateral percutaneous nephrolithotomy

• analgesic plan includes a single-injection erector spinae plane block

• age 18 years or older

Exclusion Criteria:

• morbid obesity as defined by a body mass index > 40 (BMI=weight in kg / [height in meters]2)

• renal insufficiency (abnormal preoperative creatinine or estimated glomerular filtration rate)

• chronic opioid use (daily use within the 2 weeks prior to surgery and duration of use > 4 weeks)

• history of opioid abuse

• any comorbidity which results in moderate or severe functional limitation

• inability to communicate with the investigators or hospital staff

• pregnancy

• bilateral or multi-stage surgical procedures

• incarceration

• known allergy to any study medication

• any contraindication to perineural catheter insertion (e.g., infection at the catheter insertion site)